Journal of Cellular Signaling · 2021 · 30 citations · 123 references
MedicineInfectious DiseasesPharmacologyDrug DiscoveryInnate ImmunityMolecular VirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral TherapyTreatmentViral InfectionsAntiviral Drug DesignAntiviral Natural ProductsAntiviral TherapeuticsExtracellular ProteasesSars-cov-2 Antiviral TherapySars-cov-2 InfectionSevere Acute Respiratory SyndromeTreatment Of Coronavirus Infections
The outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to coronavirus disease-19 (COVID-19); a pandemic disease that has resulted in devastating social, economic, morbidity and mortality burdens. SARS-CoV-2 infects cells following receptor-mediated endocytosis and priming by cellular proteases. Following uptake, SARS-CoV-2 replicates in autophagosome-like structures in the cytosol following its escape from endolysosomes. Accordingly, the greater endolysosome pathway including autophagosomes and the mTOR sensor may be targets for therapeutic interventions against SARS-CoV-2 infection and COVID-19 pathogenesis. Naturally existing compounds (phytochemicals) through their actions on endolysosomes and mTOR signaling pathways might provide therapeutic relief against COVID-19. Here, we discuss evidence that some natural compounds through actions on the greater endolysosome system can inhibit SARS-CoV-2 infectivity and thereby might be repurposed for use against COVID-19.
123
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Journal of Agricultural and Food Chemistry
Analytical Chemistry · 1993 · 5.9K citations